ATYR Stock — aTyr Pharma Inc.: Cash, EV, Pipeline

What they do

We are a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans.

Source: 10-K FY2025 via SEC EDGAR

Share price

$6.35

Market cap

$16.0M

Cash

$48.8M

Enterprise value

-$32.8M

Balance sheet

Cash	$48.8M
Debt	$0.0M
Net cash	$48.8M
Enterprise value	-$32.8M
Basic shares	2.5M shares
Fully diluted shares	112.6M shares
Fully diluted market cap	$715.0M
Cash per share	$19.12
Quarterly burn	$9.4M
Cash runway	6.1 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

98.1M

Pre-funded warrants

0.0M

Options

13.6M

RSUs

0.4M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.5M

FDSO

112.6M

Cap table as of 2026-06-30.

Price history

Loading ATYR daily closes…

Loading price history…

Next catalyst

efzofitimod · Est. Feb 14, 2027 · quarter midpoint · guided in 8 wks

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	efzofitimod EFZO-CONNECT Phase 2 in SSc-ILD	Phase 2	SSc-ILD	Q1 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Efzofitimod

Phase 3 · Active Modality: biologic (IV)

Target NRP2 (neuropilin-2)

Partnerships n/a (Kyorin Japan collaboration terminated effective Jul 30, 2026; Japan ILD rights reverted, company holds global rights)

Indications

Pulmonary sarcoidosis (Phase 3)
SSc-ILD (systemic sclerosis-associated ILD) (Phase 2)
Interstitial lung disease (Japan) (Phase 3)

Catalysts

— Q1 2027

Status note EFZO-FIT Phase 3 did not meet its primary endpoint (announced Sep 2025). After an FDA Type C meeting Apr 2026, the company plans a new Phase 3 with revised endpoints; protocol submitted Jun 2026. Study funding not yet secured; 60% workforce reduction Aug 2026.

ATYR0101

Preclinical · Active Modality: fusion protein (DARS domain + human Fc)

Target LTBP-1

Indications

Fibrotic diseases (pulmonary fibrosis, SSc, liver, kidney) (Preclinical)

Status note IND-enabling activities initiated; targets LTBP-1 in ECM; potential applications across pulmonary fibrosis, SSc, liver fibrosis and kidney fibrosis.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	efzofitimod 450 mg
Lead indication	Interstitial Lung Disease
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05892614	Phase 2	Recruiting	Sponsor	ATYR	—	Interstitial Lung Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for aTyr Pharma, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	50,685	no change	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ATYR — aTyr Pharma Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ATYR — aTyr Pharma Inc.